Pharmaceutical Technology

DECEMBER 4, 2022

Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market. The arrival of Humira biosimilars is expected to provide cost-effective alternatives to the anti-tumor necrosis factor (TNF) biologic, but their eventual position on the market remains to be seen.

Biosimilars 104

Biosimilars Labelling Communication Hospitals 104

Pharmaceutical Technology

DECEMBER 9, 2022

Instead, the focus remains on its domestic industry, particularly around biosimilars, while reducing reliance on imports and branded pharmaceuticals. While Brazil remains a high-growth market, investment in innovative pharmaceuticals is still limited. </p> By Tanner Pharma Group. Please check your email to download the Whitepaper.

Drug Pricing 98

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 98

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

However, low-cost generic and biosimilar manufacturers are likely to be particularly exposed to these economic pressures. By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52